FDA approves abatacept for prophylaxis of acute graft versus host disease

[FDA]

On December 15, 2021, the Food and Drug Administration approved abatacept (Orencia, Bristol-Myers Squibb Company) for the prophylaxis of acute graft versus host disease (aGVHD)


Baca selengkapnya di : http://www.fda.gov...